Adaptive Biotechnologies Corp (NASDAQ: ADPT) on Monday, soared 4.94% from the previous trading day, before settling in for the closing price of $4.45. Within the past 52 weeks, ADPT’s price has moved between $2.28 and $5.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 27.46% over the past five years. The company achieved an average annual earnings per share of 22.02%. With a float of $142.33 million, this company’s outstanding shares have now reached $145.08 million.
Let’s look at the performance matrix of the company that is accounted for 709 employees. In terms of profitability, gross margin is 49.93%, operating margin of -109.49%, and the pretax margin is -126.53%.
Adaptive Biotechnologies Corp (ADPT) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adaptive Biotechnologies Corp is 3.49%, while institutional ownership is 96.62%. The most recent insider transaction that took place on Aug 22 ’24, was worth 121,079. In this transaction SVP and General Counsel of this company sold 26,922 shares at a rate of $4.50, taking the stock ownership to the 139,365 shares. Before that another transaction happened on Aug 22 ’24, when Company’s Officer proposed sale 26,922 for $4.50, making the entire transaction worth $121,079.
Adaptive Biotechnologies Corp (ADPT) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 22.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.60% during the next five years compared to -32.91% drop over the previous five years of trading.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Adaptive Biotechnologies Corp (ADPT) is currently performing well based on its current performance indicators. A quick ratio of 3.84 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.47, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (NASDAQ: ADPT) saw its 5-day average volume 0.69 million, a negative change from its year-to-date volume of 1.42 million. As of the previous 9 days, the stock’s Stochastic %D was 18.10%. Additionally, its Average True Range was 0.30.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 59.89%, which indicates a significant increase from 26.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.22% in the past 14 days, which was lower than the 70.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.69, while its 200-day Moving Average is $3.88. Nevertheless, the first resistance level for the watch stands at $4.76 in the near term. At $4.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.99. If the price goes on to break the first support level at $4.53, it is likely to go to the next support level at $4.39. The third support level lies at $4.30 if the price breaches the second support level.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
Market capitalization of the company is 688.68 million based on 147,368K outstanding shares. Right now, sales total 170,280 K and income totals -225,250 K. The company made 43,190 K in profit during its latest quarter, and -46,220 K in sales during its previous quarter.
